Zealand Pharma logo

Zealand Pharma

Stock
Stock
ISIN: DK0060257814
Ticker: ZEAL
DK0060257814
ZEAL

Price

Price

Frequently asked questions

What is Zealand Pharma's market capitalization?

The market capitalization of Zealand Pharma is $6.92B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Zealand Pharma?

Zealand Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.331. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Zealand Pharma's stock?

Currently, 11 analysts cover Zealand Pharma's stock, with a consensus target price of $119.95. Analyst ratings provide insights into the stock's expected performance.

What is Zealand Pharma's revenue over the trailing twelve months?

Over the trailing twelve months, Zealand Pharma reported a revenue of $10.74M.

What is the EBITDA for Zealand Pharma?

Zealand Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$153.09M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Zealand Pharma?

Zealand Pharma has a free cash flow of -$99.38M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Zealand Pharma's stock?

The 5-year beta for Zealand Pharma is 1.03. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Zealand Pharma have, and what sector and industry does it belong to?

Zealand Pharma employs approximately 298 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Zealand Pharma's shares?

The free float of Zealand Pharma is 70.44M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$6.92B

5Y beta

 
1.03

EPS (TTM)

 
-$2.331

Free Float

 
70.44M

Revenue (TTM)

 
$10.74M

EBITDA (TTM)

 
-$153.09M

Free Cashflow (TTM)

 
-$99.38M

Pricing

1D span
$98.37$101.89
52W span
$45.81$142.29

Analyst Ratings

The price target is $119.95 and the stock is covered by 11 analysts.

Buy

9

Hold

2

Sell

0

Information

Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.

298

Biotechnology & Drugs

Health Care

Identifier

ISIN

DK0060257814

Primary Ticker

ZEAL

Knockouts

Join the conversation